Stay updated on LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial
Sign up to get notified when there's something new on the LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial page.

Latest updates to the LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe page’s displayed software/UI revision label changes from v3.5.2 to v3.5.3, indicating a general platform update without altering the clinical trial record itself.SummaryDifference0.1%

- Check15 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check43 days agoChange DetectedAdded revision v3.5.0 and deleted revision v3.4.3 from the study record history.SummaryDifference0.1%

- Check51 days agoChange DetectedRevision: v3.4.3 was added and Revision: v3.4.2 was removed on the history page.SummaryDifference0.1%

- Check58 days agoChange DetectedNew core study data sections were added to the record, including Adverse Events, Outcome Measures (Results), Baseline Characteristics, Participant Flow, Contacts/Locations, Study Status, and Study Identification. The history shows a new version entry (51).SummaryDifference0.6%

- Check79 days agoChange DetectedRevision: v3.4.2 was added to the history, and the funding-lapse notice and Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LGX818/MEK162 vs Vemurafenib/LGX818 in Melanoma Clinical Trial page.